NASDAQ:SBPH - Spring Bank Pharmaceuticals Stock Price, Forecast & News

Spring Bank Pharmaceuticals' stock was trading at $1.16 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SBPH stock has decreased by 17.2% and is now trading at $0.96. View which stocks have been mosted impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spring Bank Pharmaceuticals in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Spring Bank Pharmaceuticals.

Spring Bank Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Spring Bank Pharmaceuticals.

Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) released its quarterly earnings results on Friday, February, 14th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.03. View Spring Bank Pharmaceuticals' earnings history.

6 Wall Street analysts have issued 12 month price targets for Spring Bank Pharmaceuticals' stock. Their forecasts range from $1.50 to $29.00. On average, they expect Spring Bank Pharmaceuticals' share price to reach $11.84 in the next twelve months. This suggests a possible upside of 1,133.3% from the stock's current price. View analysts' price targets for Spring Bank Pharmaceuticals.

Media coverage about SBPH stock has trended somewhat negative this week, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Spring Bank Pharmaceuticals earned a media sentiment score of -1.6 on InfoTrie's scale. They also gave news articles about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View the latest news aboutSpring Bank Pharmaceuticals.

Spring Bank Pharmaceuticals saw a decrease in short interest in the month of March. As of March 13th, there was short interest totaling 35,800 shares, a decrease of 64.2% from the February 27th total of 100,000 shares. Based on an average trading volume of 136,700 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.3% of the company's shares are sold short. View Spring Bank Pharmaceuticals' Current Options Chain.

Some companies that are related to Spring Bank Pharmaceuticals include Corvus Pharmaceuticals (CRVS), Otonomy (OTIC), Sesen Bio (SESN), Synlogic (SYBX), Bellerophon Therapeutics (BLPH), Elite Pharmaceuticals (ELTP), Catalyst Biosciences (CBIO), Trevena (TRVN), Leap Therapeutics (LPTX), Oramed Pharmaceuticals (ORMP), Cumberland Pharmaceuticals (CPIX), Aridis Pharmaceuticals (ARDS), Enlivex Therapeutics (ENLV), Oncolytics Biotech (ONCY) and Milestone Pharmaceuticals (MIST).

Based on aggregate information from My MarketBeat watchlists, some companies that other Spring Bank Pharmaceuticals investors own include Intelsat (I), Fossil Group (FOSL), AMC Entertainment (AMC), Bank of America (BAC), Associated British Foods (ABF), Chaarat Gold (CGH), Strongbridge Biopharma (SBBP), Apollo Global Management (APO), SCYNEXIS (SCYX) and China Unicom (Hong Kong) (CHU).

(SBPH) raised $14 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 1,100,000 shares at a price of $12.00-$14.00 per share. Dawson James Securities acted as the underwriter for the IPO.

Spring Bank Pharmaceuticals trades on the NASDAQ under the ticker symbol "SBPH."

Spring Bank Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BVF Inc. IL (5.78%), Tiedemann Advisors LLC (2.58%), Renaissance Technologies LLC (1.22%), Hikari Power Ltd (0.80%) and Parsons Capital Management Inc. RI (0.56%). Company insiders that own Spring Bank Pharmaceuticals stock include Jonathan Freve, Martin J Driscoll and Scott Andrew Smith. View institutional ownership trends for Spring Bank Pharmaceuticals.

SBPH stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Parsons Capital Management Inc. RI, Hikari Power Ltd, and Tiedemann Advisors LLC. View insider buying and selling activity for Spring Bank Pharmaceuticals.

SBPH stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Spring Bank Pharmaceuticals stock in the last two years include Jonathan Freve, Martin J Driscoll, and Scott Andrew Smith. View insider buying and selling activity for Spring Bank Pharmaceuticals.

Shares of SBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SBPH stock can currently be purchased for approximately $0.96.

Spring Bank Pharmaceuticals has a market capitalization of $15.85 million. The company earns $-24,100,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Spring Bank Pharmaceuticals employs 29 workers across the globe. View additional information about Spring Bank Pharmaceuticals.

The official website for Spring Bank Pharmaceuticals is http://www.springbankpharm.com/.

Spring Bank Pharmaceuticals' mailing address is 35 PARKWOOD DRIVE SUITE 210, HOPKINTON MA, 01748. The company can be reached via phone at 508-473-5993 or via email at [email protected]